NO20090846L - Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav - Google Patents

Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Info

Publication number
NO20090846L
NO20090846L NO20090846A NO20090846A NO20090846L NO 20090846 L NO20090846 L NO 20090846L NO 20090846 A NO20090846 A NO 20090846A NO 20090846 A NO20090846 A NO 20090846A NO 20090846 L NO20090846 L NO 20090846L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
diabetes
treatment
combination
mammal
Prior art date
Application number
NO20090846A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090846(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Publication of NO20090846L publication Critical patent/NO20090846L/no
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En fremgangsmåte for behandling og/eller forebyggelse av diabetes mellitus, tilstander som er assosiert med diabetes mellitus og enkelte komplikasjoner derav, i et pattedyr, der fremgangsmåten innbefatter administrering av en effektiv ikke-toksisk og farmasøytisk godkjent mengde av en insulinsensitiverer og en antihyperglykemisk biguanidagens, til et pattedyr med behov derav og en Farmasøytisk blanding innbefattende en insulinsensitiverer og en antihyperglykemisk biguanidagens.
NO20090846A 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav NO20090846L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (1)

Publication Number Publication Date
NO20090846L true NO20090846L (no) 1999-12-17

Family

ID=26311745

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
NO20063000A NO326958B1 (no) 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav.
NO2008003C NO2008003I2 (no) 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid
NO20090846A NO20090846L (no) 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
NO20063000A NO326958B1 (no) 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav.
NO2008003C NO2008003I2 (no) 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid

Country Status (38)

Country Link
US (3) US20060100247A1 (no)
EP (2) EP1787646A3 (no)
JP (1) JP2002504137A (no)
KR (2) KR20060105005A (no)
CN (2) CN1114404C (no)
AP (1) AP1279A (no)
AR (2) AR012998A1 (no)
AT (1) ATE355840T1 (no)
AU (1) AU8539398A (no)
BG (2) BG64818B1 (no)
BR (1) BR9810172A (no)
CA (1) CA2294582C (no)
CY (2) CY1107643T1 (no)
CZ (1) CZ298469B6 (no)
DE (2) DE122007000054I1 (no)
DK (1) DK0996444T3 (no)
DZ (1) DZ2520A1 (no)
EA (1) EA003144B1 (no)
ES (1) ES2284212T3 (no)
ID (1) ID23372A (no)
IL (3) IL133142A0 (no)
IN (1) IN189722B (no)
LU (1) LU91356I2 (no)
MA (1) MA26512A1 (no)
MY (1) MY129897A (no)
NL (1) NL300288I2 (no)
NO (4) NO324993B1 (no)
NZ (1) NZ501260A (no)
OA (1) OA11516A (no)
PE (1) PE83199A1 (no)
PL (2) PL195136B1 (no)
PT (1) PT996444E (no)
SI (1) SI0996444T1 (no)
SK (1) SK286029B6 (no)
TR (1) TR199903057T2 (no)
TW (1) TW565449B (no)
UY (1) UY25049A1 (no)
WO (1) WO1998057634A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU765498B2 (en) 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
KR20070089259A (ko) 1999-11-03 2007-08-30 브리스톨-마이어스스퀴브컴파니 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CA2725833A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
KR20120034211A (ko) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
JPWO2006011397A1 (ja) * 2004-07-27 2008-05-01 興和株式会社 糖尿病の予防または治療のための薬剤
WO2006086727A2 (en) * 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
TW200740460A (en) * 2005-07-12 2007-11-01 Sankyo Co Pharmaceutical composition containing PPAR γ agonist
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
WO2010012650A1 (en) * 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
FI974437A0 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
US20080090881A1 (en) 2008-04-17
CA2294582A1 (en) 1998-12-23
AR012995A1 (es) 2000-11-22
PL195136B1 (pl) 2007-08-31
CA2294582C (en) 2008-02-12
IN189722B (no) 2003-04-19
SK179299A3 (en) 2000-11-07
TW565449B (en) 2003-12-11
NO2008003I2 (no) 2010-06-28
IL133142A (en) 2006-06-11
EP0996444B1 (en) 2007-03-07
HK1028193A1 (en) 2001-02-09
EP1787646A3 (en) 2007-10-03
PT996444E (pt) 2007-06-08
DE69837261T2 (de) 2007-11-08
CN1429551A (zh) 2003-07-16
CY1107643T1 (el) 2012-01-25
NZ501260A (en) 2002-09-27
AP1279A (en) 2004-05-20
PL195140B1 (pl) 2007-08-31
EA200000041A1 (ru) 2000-08-28
US20060100247A1 (en) 2006-05-11
IL133142A0 (en) 2001-03-19
AU8539398A (en) 1999-01-04
JP2002504137A (ja) 2002-02-05
NO20063000L (no) 1999-12-17
AP9901719A0 (en) 1999-12-31
NO996266L (no) 1999-12-17
ID23372A (id) 2000-04-20
KR20060105005A (ko) 2006-10-09
IL173650A0 (en) 2006-07-05
DK0996444T3 (da) 2007-07-02
NL300288I1 (nl) 2007-11-01
PE83199A1 (es) 1999-10-22
KR100666591B1 (ko) 2007-01-11
WO1998057634A1 (en) 1998-12-23
OA11516A (en) 2004-02-04
SK286029B6 (sk) 2008-01-07
BG109398A (bg) 2006-05-31
ATE355840T1 (de) 2007-03-15
SI0996444T1 (sl) 2007-08-31
NL300288I2 (nl) 2009-06-02
UY25049A1 (es) 2000-09-29
BR9810172A (pt) 2000-08-08
NO324993B1 (no) 2008-01-14
KR20010013844A (ko) 2001-02-26
AR012998A1 (es) 2000-11-22
MA26512A1 (fr) 2004-12-20
BG104060A (en) 2000-10-31
LU91356I2 (fr) 2008-01-29
NO996266D0 (no) 1999-12-17
DE69837261D1 (de) 2007-04-19
MY129897A (en) 2007-05-31
TR199903057T2 (xx) 2000-04-21
DE122007000054I1 (de) 2007-12-13
NO326958B1 (no) 2009-03-23
NO2008003I1 (no) 2008-04-21
EA003144B1 (ru) 2003-02-27
CN1260716A (zh) 2000-07-19
PL337362A1 (en) 2000-08-14
CZ298469B6 (cs) 2007-10-10
BG64818B1 (bg) 2006-05-31
US20070004780A1 (en) 2007-01-04
DZ2520A1 (fr) 2003-02-01
ES2284212T3 (es) 2007-11-01
CN1230171C (zh) 2005-12-07
EP0996444A1 (en) 2000-05-03
CZ9904578A3 (en) 2001-06-13
CN1114404C (zh) 2003-07-16
CY2007018I1 (el) 2012-01-25
EP1787646A2 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
BR9810444A (pt) Tratamento de diabete com rosiglitazona e insulina
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
NO996270L (no) Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor
BR9810904A (pt) Tramento de diabetes com tiazolidinodiona e sulfoniluréia
RU96115219A (ru) Способ лечения больных сахарным диабетом
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
ES2135353A1 (es) Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP982591A (es) Nuevo metodo de tratamiento iv
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982541A (es) Nuevo metodo de tratamiento ii
CO5150158A1 (es) Tratamiento antidiabetico novedoso
ECSP982592A (es) Nuevo metodo de tratamiento v
BR9815220A (pt) Uso de tiazolidinedionas para o tratamento da hiperglicemia
ECSP982593A (es) Nuevo metodo de tratamiento vi
BR9815219A (pt) Uso de tiazolidinedionas para o tratamento da hiperglicemia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application